◎ Sugi Atlas

Atlas / Disease / Primary hyperparathyroidism

Primary hyperparathyroidism

disease
On this page

Also known as primary hyperparathyroidism (disease)

Summary

Primary hyperparathyroidism (MONDO:0010837) is a disease with 4 cohort genes and 67 clinical trials. Top therapeutic interventions include cinacalcet, cholecalciferol, and zoledronic acid anhydrous.

At a glance

  • Cohort genes: 4
  • ClinVar variants: 9
  • Clinical trials: 67

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameprimary hyperparathyroidism
Mondo IDMONDO:0010837
EFOEFO:0008519
MeSHD049950
DOIDDOID:11202
ICD-10-CME21.0
ICD-11817194045
NCITC48280
SNOMED CT36348003
UMLSC0221002
MedGen66354
Is cancer (heuristic)no

Also known as: primary hyperparathyroidism · primary hyperparathyroidism (disease)

Data availability: 9 ClinVar variants · 1 HPO phenotype.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › parathyroid gland disorder › hyperparathyroidism › primary hyperparathyroidism

Related subtypes (3): secondary hyperparathyroidism, hereditary hyperparathyroidism, tertiary hyperparathyroidism

Subtypes (1): familial primary hyperparathyroidism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

9 retrieved; paginated sample, class counts are floors:

5 conflicting classifications of pathogenicity, 2 pathogenic, 1 likely pathogenic, 1 pathogenic/likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
8312NM_000388.4(CASR):c.2383C>T (p.Arg795Trp)CASRPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
217128NM_001370259.2(MEN1):c.152del (p.Asn51fs)MEN1Pathogeniccriteria provided, single submitter
523339NM_001370259.2(MEN1):c.371_372del (p.Val124fs)MEN1Pathogeniccriteria provided, single submitter
13759NM_000315.4(PTH):c.247C>T (p.Arg83Ter)PTHLikely pathogeniccriteria provided, single submitter
217125NM_004064.5(CDKN1B):c.-80C>TCDKN1BConflicting classifications of pathogenicitycriteria provided, conflicting classifications
217126NM_004064.5(CDKN1B):c.-31AG[1]CDKN1BConflicting classifications of pathogenicitycriteria provided, conflicting classifications
217127NM_004064.5(CDKN1B):c.397C>A (p.Pro133Thr)CDKN1BConflicting classifications of pathogenicitycriteria provided, conflicting classifications
650858NM_004064.5(CDKN1B):c.216C>T (p.Gly72=)CDKN1BConflicting classifications of pathogenicitycriteria provided, conflicting classifications
41852NM_001370259.2(MEN1):c.1621= (p.Thr541=)MEN1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
CASROrphanet:417Neonatal severe primary hyperparathyroidism
CASROrphanet:428Autosomal dominant hypocalcemia
CASROrphanet:676Autosomal dominant hereditary chronic pancreatitis
CASROrphanet:93372Familial hypocalciuric hypercalcemia type 1
CDKN1BOrphanet:276152Multiple endocrine neoplasia type 4
CDKN1BOrphanet:652Multiple endocrine neoplasia type 1
MEN1Orphanet:2965Prolactinoma
MEN1Orphanet:314786Silent pituitary adenoma
MEN1Orphanet:314790Null pituitary adenoma
MEN1Orphanet:652Multiple endocrine neoplasia type 1
MEN1Orphanet:97279Insulinoma
MEN1Orphanet:99725Pituitary gigantism
MEN1Orphanet:99879Familial isolated hyperparathyroidism
PTHOrphanet:189466Familial isolated hypoparathyroidism due to impaired PTH secretion

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence4

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
CASRHGNC:1514ENSG00000036828P41180Extracellular calcium-sensing receptorclinvar
CDKN1BHGNC:1785ENSG00000111276P46527Cyclin-dependent kinase inhibitor 1Bclinvar
MEN1HGNC:7010ENSG00000133895O00255Meninclinvar
PTHHGNC:9606ENSG00000152266P01270Parathyroid hormoneclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
CASRExtracellular calcium-sensing receptorG-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis.
CDKN1BCyclin-dependent kinase inhibitor 1BImportant regulator of cell cycle progression.
MEN1MeninEssential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates ‘Lys-4’ of histone H3 (H3K4).
PTHParathyroid hormoneParathyroid hormone elevates calcium level by dissolving the salts in bone and preventing their renal excretion.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
GPCR16.0×0.314
Other/Unknown31.3×0.404

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
CASRGPCRyesGPCR_3_Ca_sens_rcpt-rel, GPCR_3, ANF_lig-bd_rcpt
CDKN1BOther/UnknownnoCDI_dom, CDI_dom_sf
MEN1Other/UnknownnoMenin
PTHOther/UnknownnoPTH/PTH-rel, PTH

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)4
unknown0

Top tissues across cohort

TissueCohort genes
pigmented layer of retina2
diaphragm1
hair follicle1
islet of Langerhans1
retina1
ventricular zone1
granulocyte1
lower esophagus mucosa1
right hemisphere of cerebellum1
endometrium epithelium1
male germ line stem cell (sensu Vertebrata) in testis1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
CASR63tissue_specificmarkerislet of Langerhans, diaphragm, hair follicle
CDKN1B301ubiquitousmarkerpigmented layer of retina, retina, ventricular zone
MEN1271ubiquitousmarkergranulocyte, lower esophagus mucosa, right hemisphere of cerebellum
PTH94tissue_specificmarkermale germ line stem cell (sensu Vertebrata) in testis, pigmented layer of retina, endometrium epithelium

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

SymbolInteractor count
MEN15,226
CDKN1B4,635
CASR2,692
PTH1,967

Intra-cohort edges

ABSources
CASRMEN1string_interaction
CASRPTHstring_interaction
MEN1PTHstring_interaction

Structural data

PDB: 4 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
MEN1O0025569
CASRP4118031
PTHP0127026
CDKN1BP4652719

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 78. Enrichment computed across 4 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
PTK6 Regulates Cell Cycle1475.8×0.033CDKN1B
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects1219.6×0.033CDKN1B
AKT phosphorylates targets in the cytosol1203.9×0.033CDKN1B
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest1178.4×0.033CDKN1B
p53-Dependent G1 DNA Damage Response1178.4×0.033CDKN1B
p53-Dependent G1/S DNA damage checkpoint1178.4×0.033CDKN1B
G1/S DNA Damage Checkpoints1167.9×0.033CDKN1B
FOXO-mediated transcription of cell cycle genes1167.9×0.033CDKN1B
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)1158.6×0.033CDKN1B
RHO GTPases activate CIT1150.3×0.033CDKN1B
TP53 Regulates Transcription of Cell Cycle Genes1135.9×0.033CDKN1B
Signaling by PTK61135.9×0.033CDKN1B
Signaling by Non-Receptor Tyrosine Kinases1135.9×0.033CDKN1B
Estrogen-dependent nuclear events downstream of ESR-membrane signaling1109.8×0.033CDKN1B
Constitutive Signaling by AKT1 E17K in Cancer1105.7×0.033CDKN1B
Aberrant regulation of mitotic cell cycle due to RB1 defects1102.0×0.033CDKN1B
G1 Phase198.5×0.033CDKN1B
Diseases of mitotic cell cycle198.5×0.033CDKN1B
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer192.1×0.033MEN1
PI3K/AKT Signaling in Cancer192.1×0.033CDKN1B
RHO GTPases activate IQGAPs186.5×0.033MEN1
FLT3 Signaling186.5×0.033CDKN1B
FOXO-mediated transcription184.0×0.033CDKN1B
RHO GTPase Effectors234.0×0.033CDKN1B, MEN1
Signaling by Rho GTPases217.1×0.033CDKN1B, MEN1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3216.7×0.033CDKN1B, MEN1
RNA Polymerase II Transcription211.3×0.033CDKN1B, MEN1
Signal Transduction37.6×0.033CASR, CDKN1B, MEN1
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription177.2×0.035MEN1
Class C/3 (Metabotropic glutamate/pheromone receptors)173.2×0.035CASR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
response to fibroblast growth factor21053.2×1e-04CASR, PTH
macromolecule biosynthetic process14213.0×0.008PTH
regulation of presynaptic membrane potential12106.5×0.008CASR
adenylate cyclase-activating G protein-coupled cAMP receptor signaling pathway12106.5×0.008PTH
regulation of lens fiber cell differentiation12106.5×0.008CDKN1B
negative regulation of cardiac muscle tissue regeneration12106.5×0.008CDKN1B
intracellular calcium ion homeostasis272.6×0.008CASR, PTH
negative regulation of apoptotic process in bone marrow cell11404.3×0.008PTH
cAMP metabolic process11053.2×0.008PTH
response to parathyroid hormone11053.2×0.008PTH
positive regulation of cell proliferation in bone marrow11053.2×0.008PTH
positive regulation of osteoclast proliferation11053.2×0.008PTH
negative regulation of bone mineralization involved in bone maturation11053.2×0.008PTH
chemosensory behavior1842.6×0.008CASR
hormone-mediated apoptotic signaling pathway1842.6×0.008PTH
bile acid secretion1842.6×0.008CASR
autophagic cell death1842.6×0.008CDKN1B
negative regulation of epithelial cell proliferation involved in prostate gland development1702.2×0.009CDKN1B
positive regulation of inositol phosphate biosynthetic process1601.9×0.010PTH
cellular response to antibiotic1601.9×0.010CDKN1B
negative regulation of cyclin-dependent protein serine/threonine kinase activity1526.6×0.010MEN1
epithelial cell proliferation involved in prostate gland development1526.6×0.010CDKN1B
magnesium ion homeostasis1468.1×0.010PTH
T-helper 2 cell differentiation1468.1×0.010MEN1
fat pad development1421.3×0.010CASR
cellular response to peptide1421.3×0.010CASR
nuclear export1383.0×0.010CDKN1B
cellular response to vitamin D1383.0×0.010CASR
regulation of cell cycle G1/S phase transition1383.0×0.010CDKN1B
positive regulation of positive chemotaxis1351.1×0.011CASR

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amiloride, Calcium, Cinacalcet, Eplerenone.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 2

Druggability breadth: 3 of 4 evidence-associated genes (75%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
CASRCINACALCET HYDROCHLORIDE
MEN1LOPERAMIDE

Top cohort targets by molecule count

SymbolMoleculesMax phase
MEN14754
CASR104
CDKN1B00
PTH00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
CINACALCET HYDROCHLORIDE4CASR
CINACALCET4CASR
LOPERAMIDE4MEN1
CANDESARTAN CILEXETIL4MEN1
EVANS BLUE FREE ACID4MEN1
DIENESTROL4MEN1
BEXAROTENE4MEN1
IFOSFAMIDE4MEN1
PROGESTERONE4MEN1
CLOTRIMAZOLE4MEN1
AMINOCAPROIC ACID4MEN1
LATANOPROST4MEN1
FLUORESCEIN4MEN1
OXCARBAZEPINE4MEN1
SALMETEROL XINAFOATE4MEN1
AMIODARONE HYDROCHLORIDE4MEN1
TRICLABENDAZOLE4MEN1
TRYPAN BLUE FREE ACID4MEN1
MIGALASTAT4MEN1
DROPERIDOL4MEN1
ARIPIPRAZOLE4MEN1
AMOXAPINE4MEN1
RALOXIFENE HYDROCHLORIDE4MEN1
IDARUBICIN4MEN1
ACETAMINOPHEN4MEN1
OXYBUTYNIN CHLORIDE4MEN1
DECAMETHONIUM BROMIDE4MEN1
DESLORATADINE4MEN1
DITHIAZANINE4MEN1
TRIMETREXATE4MEN1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
MEN193Binding:86, Functional:7
CASR45Functional:32, Binding:13
CDKN1B5Binding:5

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
CINACALCET HYDROCHLORIDE4CASR
LOPERAMIDE4MEN1
CANDESARTAN CILEXETIL4MEN1
EVANS BLUE FREE ACID4MEN1
DIENESTROL4MEN1
BEXAROTENE4MEN1
IFOSFAMIDE4MEN1
PROGESTERONE4MEN1
CLOTRIMAZOLE4MEN1
AMINOCAPROIC ACID4MEN1
LATANOPROST4MEN1
FLUORESCEIN4MEN1
OXCARBAZEPINE4MEN1
SALMETEROL XINAFOATE4MEN1
AMIODARONE HYDROCHLORIDE4MEN1
TRICLABENDAZOLE4MEN1
TRYPAN BLUE FREE ACID4MEN1
MIGALASTAT4MEN1
DROPERIDOL4MEN1
ARIPIPRAZOLE4MEN1
AMOXAPINE4MEN1
RALOXIFENE HYDROCHLORIDE4MEN1
IDARUBICIN4MEN1
ACETAMINOPHEN4MEN1
OXYBUTYNIN CHLORIDE4MEN1
DECAMETHONIUM BROMIDE4MEN1
DESLORATADINE4MEN1
DITHIAZANINE4MEN1
TRIMETREXATE4MEN1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)2CASR, MEN1
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2CDKN1B, PTH

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
PTH0CASR
CDKN1B5—

Clinical trials & evidence

Clinical trials

Clinical trials: 67.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified47
PHASE46
PHASE2/PHASE34
PHASE24
PHASE33
PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03935984PHASE4RECRUITINGCalcitonin Pre-treatment to Improve SPECT-CT Sensitivity
NCT06859580PHASE4RECRUITINGBisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism
NCT01222026PHASE4COMPLETEDSystematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
NCT01306656PHASE4COMPLETEDVitamin D Repletion in Primary Hyperparathyroidism
NCT01558115PHASE4TERMINATEDDenosumab in Primary Hyperparathyroidism
NCT04085419PHASE4UNKNOWNOsteoporosis in Primary Hyperparathyroidism
NCT07444723PHASE2/PHASE3RECRUITINGAccuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
NCT00674154PHASE2/PHASE3COMPLETEDEffect of Vitamin D Treatment in Primary Hyperparathyroidism
NCT01329666PHASE2/PHASE3WITHDRAWNPrimary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
NCT01460030PHASE3COMPLETEDAn Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
NCT02525796PHASE2/PHASE3COMPLETEDEvaluating Alternative Medical Therapies in Primary Hyperparathyroidism
NCT03027557PHASE3COMPLETEDTreatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
NCT03280264PHASE3COMPLETEDPhase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
NCT00973336PHASE2UNKNOWNPrimary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?
NCT01783002PHASE2UNKNOWN11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
NCT03774771PHASE2COMPLETEDSafety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
NCT03776058PHASE2COMPLETEDSafety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
NCT01598727PHASE1COMPLETEDNear Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics
NCT01996072PHASE1COMPLETEDEC17 for Intraoperative Imaging for Parathyroidectomy
NCT04844164PHASE1COMPLETEDVitamin D Metabolism in Patients With Endocrine Disorders
NCT03039439Not specifiedRECRUITINGMolecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
NCT04969926Not specifiedRECRUITINGNatural History Study of Parathyroid Disorders
NCT05469087Not specifiedRECRUITINGCohort Primary Hyperparathyroidism
NCT05761743Not specifiedACTIVE_NOT_RECRUITINGGlycemic Control, Type II Diabetes, Parathyroidectomy
NCT05997810Not specifiedRECRUITINGParathyroid Tumor Clonal Status
NCT06523582Not specifiedRECRUITINGGenetic Bases of Neuroendocrine Neoplasms in Mexican Patients
NCT06647966Not specifiedNOT_YET_RECRUITINGDiagnostic Performance of [11C]Choline PET/CT In the Preoperative Assessment of Primary Hyperparathyroidism
NCT06804681Not specifiedNOT_YET_RECRUITINGIs Intraoperative PTH Monitoring Obsolete in Times of Choline PET/CT? a Prospective Multicenter Cohort Study to Determine Whether the Regular Preoperative Use of Choline-PET/CT Scan Obviate the Need for Intraoperative PTH-measurement in Patients with Primary Hyperparathyreoidism
NCT07138820Not specifiedRECRUITING18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased Parathyroid Glands in Primary Hyperparathyroidism
NCT07379463Not specifiedRECRUITINGAmino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
NCT07388914Not specifiedNOT_YET_RECRUITINGAldosterone Variations in Patients With Primary Hyperparathyroidism After Surgery
NCT00432939Not specifiedCOMPLETEDPrimary Hyperparathyroidism: Non-classical Manifestations
NCT00522028Not specifiedCOMPLETEDAsymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial
NCT00877981Not specifiedCOMPLETEDOpen Versus Video-Assisted Minimal-Invasive Parathyroid Surgery
NCT00961701Not specifiedTERMINATEDLipids Profile in Primary Hyperparathyroidism
NCT00982722Not specifiedCOMPLETEDVitamin D Supplementation After Parathyroid Surgery
NCT01057732Not specifiedCOMPLETEDEffects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism
NCT01087619Not specifiedCOMPLETEDSurgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up
NCT01228786Not specifiedUNKNOWNRegulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism
NCT01409798Not specifiedCOMPLETEDThe Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CINACALCET413
CHOLECALCIFEROL46
ZOLEDRONIC ACID ANHYDROUS46
DENOSUMAB42
PARATHYROID HORMONE42
AMILORIDE41
CALCITONIN41
CALCIUM41
CALCIUM CARBONATE41
EPLERENONE41
ERGOCALCIFEROL41
EVOCALCET31
FLUOROCHOLINE F-1831
CHEMBL507282601

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 72

This page pulls from 72 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot